A Breakthrough Drug for Allergic Reactions

The FDA has recently announced a new drug that could change the lives of people with common food allergies. Xolair is a revolutionary drug designed to diminish the severity of allergic reactions to foods such as milk, eggs, walnuts, and peanuts. The first drug of its kind, Xolair is not an emergency cure for someone who has been exposed to an allergen, rather it is a preventive drug, administered every few weeks to progressively lower the risk of allergic reactions.

According to Kelly Stone of the FDA Center for Drug Evaluation and Research, “While it will not eliminate food allergies or allow patients to consume food allergens freely, its repeated use will help reduce the health impact if accidental exposure occurs”.

Developed by Genentech and Novartis, Xolair’s introduction represents an exciting breakthrough in the world of allergies. While currently being offered at the high price of $2,900 and $5,000 a month for pediatric and adult patients respectively, insurance coverage may alleviate the cost burden.

Xolair showed significant promise in trials, significantly reducing allergic reactions to peanuts, eggs, milk, and cashews. Its approval is a testament to the strides being made in allergy management.

About James Cannon

James Cannon is an experienced hedge fund analyst. He has served on the advisory boards for various different Fortune 500 companies as well as serving as an adjunct professor of finance. James Cannon has written for a variety of Financial Magazines both on and off line. Contact James at james[at]businessdistrict.com